Sino Biopharmaceutical Crecimiento futuro

Future controles de criterios 2/6

Sino Biopharmaceutical se prevé un crecimiento anual de los beneficios y los ingresos de 14.4% y 5.8% respectivamente. Se prevé que el BPA sea de grow en 20.3% al año. Se prevé que la rentabilidad de los fondos propios sea de 10.5% en 3 años.

Información clave

15.3%

Tasa de crecimiento de los beneficios

18.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	12.8%
Tasa de crecimiento de los ingresos	7.1%
Rentabilidad financiera futura	9.0%
Cobertura de analistas	Good
Última actualización	12 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

SZSC:1177 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	34,324	3,349	5,928	N/A	13
12/31/2025	32,858	3,267	4,780	N/A	24
12/31/2024	29,092	2,860	5,129	N/A	19
12/31/2023	26,199	1,847	N/A	N/A	N/A
6/30/2023	28,864	1,881	3,314	4,987	N/A
3/31/2023	28,822	2,212	4,017	5,626	N/A
12/31/2022	28,780	2,544	4,719	6,265	N/A
9/30/2022	28,241	5,296	4,895	6,622	N/A
6/30/2022	27,701	8,049	5,071	6,980	N/A
3/31/2022	27,215	13,655	N/A	N/A	N/A
12/31/2021	26,861	14,608	3,499	5,366	N/A
9/30/2021	26,129	12,465	N/A	N/A	N/A
6/30/2021	25,353	10,011	4,337	6,105	N/A
3/31/2021	24,668	3,809	N/A	N/A	N/A
12/31/2020	23,647	2,771	3,537	5,325	N/A
9/30/2020	23,039	2,302	N/A	N/A	N/A
6/30/2020	24,354	2,558	1,827	3,373	N/A
3/31/2020	24,248	2,781	N/A	N/A	N/A
12/31/2019	24,234	2,762	3,622	5,325	N/A
9/30/2019	24,479	9,101	N/A	N/A	N/A
6/30/2019	23,691	9,125	4,774	6,543	N/A
3/31/2019	22,444	9,132	N/A	N/A	N/A
12/31/2018	20,889	9,046	3,417	5,094	N/A
9/30/2018	19,103	2,567	N/A	N/A	N/A
6/30/2018	17,062	2,436	1,231	2,572	N/A
3/31/2018	15,609	2,363	N/A	N/A	N/A
12/31/2017	14,819	2,171	2,624	3,733	N/A
9/30/2017	14,491	2,115	N/A	N/A	N/A
6/30/2017	14,258	1,862	N/A	4,773	N/A
3/31/2017	13,899	1,789	N/A	N/A	N/A
12/31/2016	13,543	1,637	N/A	2,995	N/A
9/30/2016	13,271	1,674	N/A	N/A	N/A
6/30/2016	12,858	1,604	N/A	1,757	N/A
3/31/2016	12,507	1,575	N/A	N/A	N/A
12/31/2015	12,189	1,490	N/A	1,919	N/A
9/30/2015	12,030	1,432	N/A	N/A	N/A
6/30/2015	11,124	1,447	N/A	1,973	N/A
3/31/2015	10,552	1,263	N/A	N/A	N/A
12/31/2014	9,900	1,210	N/A	1,840	N/A
9/30/2014	9,205	1,074	N/A	N/A	N/A
6/30/2014	8,876	951	N/A	2,000	N/A
3/31/2014	8,434	886	N/A	N/A	N/A
12/31/2013	7,731	809	N/A	1,230	N/A
9/30/2013	8,069	868	N/A	N/A	N/A
6/30/2013	6,902	815	N/A	1,292	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 1177(14.4% al año) es superior a la tasa de ahorro (2%).

Beneficios frente mercado: 1177Se prevé que los beneficios de la empresa (14.4% al año) crezcan más deprisa que el mercado Hong Kong (12.8% al año).

Beneficios de alto crecimiento: 1177Se prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: 1177(5.8% al año) se prevé que crezca más despacio que el mercado de Hong Kong (8.5% al año).

Ingresos de alto crecimiento: 1177Se prevé que los ingresos de la empresa (5.8% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 1177Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (10.5%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Sino Biopharmaceutical Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Recent updates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Upcoming dividend of HK$0.06 per share

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021)

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Upcoming dividend of HK$0.04 per share

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"

Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020)

Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial

Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication

Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE

Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China

Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020)

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022

Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial

Investor sentiment improved over the past week

Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing

Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration

Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial

Founder & Senior Vice Chairman recently bought HK$29m worth of stock

VP & Executive Director recently bought HK$12m worth of stock

Second quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.019 in 2Q 2020)

Founder & Senior Vice Chairman recently bought HK$101m worth of stock

Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China

Founder & Senior Vice Chairman recently bought HK$98m worth of stock

Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate

Upcoming dividend of HK$0.02 per share

Sino Biopharmaceutical Limited Announces That the Phase Iii Clinical Trial Results of "Anlotinib Hydrochloride Capsules

Sino Biopharmaceutical Limited Announces "Tolvaptan Tablets" Obtains Drug Registration Certificate

Sino Biopharmaceutical Limited Announces "Sunitinib Malate Capsules" Obtains Drug Registration Certificate

VP & Executive Director recently bought HK$8.8m worth of stock

First quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.046 in 1Q 2020)

Sino Biopharmaceutical Limited Declares Dividend for the Three Months Ended 31 March, 2021, Payable on 12 July, 2021

Full year 2020 earnings released: EPS CN¥0.15 (vs CN¥0.15 in FY 2019)

Sino Biopharmaceutical Limited Announces "Decitabine for Injection" Passes Consistency Evaluation

Sino Biopharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 23, 2021